SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-001112
Filing Date
2022-01-04
Accepted
2022-01-04 08:14:34
Documents
14
Period of Report
2022-01-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d255228d8k.htm   iXBRL 8-K 24919
2 EX-99.1 d255228dex991.htm EX-99.1 10977
3 EX-99.2 d255228dex992.htm EX-99.2 11831
  Complete submission text file 0001193125-22-001112.txt   183587

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA spro-20220103.xsd EX-101.SCH 2914
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20220103_lab.xml EX-101.LAB 18886
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20220103_pre.xml EX-101.PRE 11874
8 EXTRACTED XBRL INSTANCE DOCUMENT d255228d8k_htm.xml XML 3482
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 22504142
SIC: 2834 Pharmaceutical Preparations